Delving into the Latest Updates on humLpMab-23-f with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

humLpMab 23-f

Target

PDPN

Mechanism

PDPN inhibitors(podoplanin inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesRespiratory Diseases+ [1]

Active Indication

GlioblastomaSquamous non-small cell lung cancer

Inactive Indication-

Originator Organization

Tohoku University

Active Organization

Tohoku University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

A cancer-specific anti-PDPN mAb, LpMab-23 (mouse IgG1, kappa), was established in our previous study. We herein produced a humanized IgG1 version (humLpMab-23) and defucosylated form (humLpMab-23-f) of an anti-PDPN mAb to increase ADCC activity. humLpMab-23 recognized PDPN-overexpressed Chinese hamster ovary (CHO)-K1 (CHO/PDPN), PDPN-positive PC-10 (human lung squamous cell carcinoma), and LN319 (human glioblastoma) cells via flow cytometry. We then demonstrated that humLpMab-23-f induced ADCC and complement-dependent cytotoxicity against CHO/PDPN, PC-10, and LN319 cells in vitro and exerted high antitumor activity in mouse xenograft models, indicating that humLpMab-23-f could be useful as an antibody therapy against PDPN-positive lung squamous cell carcinomas and glioblastomas.

100 Deals associated with humLpMab-23-f

Login to view more data